• 1
    Abuannadi M, O'Keefe JH. Eplerenone: an underused medication? J Cardiovasc Pharmacol Ther. 2010;15:318325.
  • 2
    Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53:286290.
  • 3
    Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341:753755.
  • 4
    Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralo-corticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:25592565.
  • 5
    Iraqu W, Rossignoi P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009;119:24712479.
  • 6
    Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:12281233.
  • 7
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709717.
  • 8
    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:13091321.
  • 9
    O'Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab. 2008;10:492497.
  • 10
    Zannad F, McMurray JJV, Krum H, et al., for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:1121.
  • 11
    Bangalore S, Kumar S, Messerli FH. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor or aldosterone antagonist. Congest Heart Fail 2012; DOI: 10.1111/chf.12011 [Epub ahead of print].
  • 12
    McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM trial. Lancet. 2003;362:767771.
  • 13
    Kuenzli A, Bucher HC, Anand I, et al. Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS ONE. 2010;5:e9946.
  • 14
    FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna). U.S. Food and Drug Administration – Protecting and Promoting Your Health, accessed online November 21, 2012.
  • 15
    Hernandez AF, Mi X, Hammill BG, et al. Association between aldosterone antagonist therapy and mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308:20972107.
  • 16
    Busch E, Ventura HO, Lavie CJ. Heparin-induced hyperkalemia. South Med J. 1987;80:14501451.
  • 17
    DiNicolantonio JJ, Lavie CJ, Fares H, et al. Aldosterone antagonists for the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Submitted 2013.